Financial results for the period ended Jun 30, 2026
As filed · Nath Bio-Genes (India) Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactNathbiogen's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 during their meeting on 29th July 2026. They also scheduled the 33rd Annual General Meeting for 24th September 2026 at 11:00 a.m. via video conference. Further details regarding participation and book closure will be provided separately.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedVegetables: Robust growth of 60% in value and 76% in quantity, driven by higher market penetration and new product launches.
Maize: Strong 47% YoY growth on the back of improved product acceptance.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- This year, you will see the significant improvement by the end of this quarter, you will realize what kind of (management committed by Q4 FY26)
- Within next three years' time, Nath would be either similar to Kaveri or better to Kaveri in hybrid segment. (management committed by FY27)
Evidence
- Exchange filing(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%